Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.
Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, Simpson E, Genge A, Bertorini T, Fernandes JA, Swenson A, Elman L, Dimachkie M, Herbelin L, Miller J, Lu J, Wilkins H, Swerdlow RH, Statland J, Barohn R; Western ALS (WALS) Rasagiline Study Group. Macchi Z, et al. Among authors: barohn r. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):345-52. doi: 10.3109/21678421.2015.1026826. Epub 2015 Apr 2. Amyotroph Lateral Scler Frontotemporal Degener. 2015. PMID: 25832828 Free PMC article.
Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies ANTXR2 as a candidate in PLS.
Pottinger TD, Motelow JE, Povysil G, Moreno CAM, Ren Z, Phatnani H; New York Genome Center ALS Sequencing Consortium; Aitman TJ, Santoyo-Lopez J; Scottish Genomes Partnership; Mitsumoto H; ALS COSMOS Study Group; PLS COSMOS Study Group; GTAC Investigators; Goldstein DB, Harms MB. Pottinger TD, et al. BMC Genomics. 2024 Jun 29;25(1):651. doi: 10.1186/s12864-024-10538-1. BMC Genomics. 2024. PMID: 38951798 Free PMC article.
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis.
Bhai S, Levine T, Moore D, Bowser R, Heim AJ, Walsh M, Shibani A, Simmons Z, Grogan J, Goyal NA, Govindarajan R, Hussain Y, Papsdorf T, Schwasinger-Schmidt T, Olney N, Goslin K, Pulley M, Kasarskis E, Weiss M, Katz SW, Moser S, Jabari D, Jawdat O, Statland J, Dimachkie MM, Barohn R; Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group. Bhai S, et al. Among authors: barohn r. Muscle Nerve. 2025 Jan;71(1):63-72. doi: 10.1002/mus.28287. Epub 2024 Nov 7. Muscle Nerve. 2025. PMID: 39511965 Free PMC article. Clinical Trial.
Resistance exercise in early-stage ALS patients, ALSFRS-R, Sickness Impact Profile ALS-19, and muscle transcriptome: a pilot study.
Jawdat O, Rucker J, Nakano T, Takeno K, Statland J, Pasnoor M, Dimachkie MM, Sabus C, Badawi Y, Hunt SL, Tomioka NH, Gunewardena S, Bloomer C, Wilkins HM, Herbelin L, Barohn RJ, Nishimune H. Jawdat O, et al. Among authors: barohn rj. Sci Rep. 2024 Sep 17;14(1):21729. doi: 10.1038/s41598-024-72355-6. Sci Rep. 2024. PMID: 39289471 Free PMC article. Clinical Trial.
Myasthenia gravis.
Pasnoor M, Wolfe GI, Barohn RJ. Pasnoor M, et al. Among authors: barohn rj. Handb Clin Neurol. 2024;203:185-203. doi: 10.1016/B978-0-323-90820-7.00006-9. Handb Clin Neurol. 2024. PMID: 39174248 Review.
Measurement properties of the Inclusion Body Myositis Functional Rating Scale.
Salam S, Symonds T, Doll H, Rousell S, Randall J, Lloyd-Price L, Hudgens S, Guldberg C, Herbelin L, Barohn RJ, Hanna MG, Dimachkie MM, Machado PM; Members of the Arimoclomol in IBM Investigator Team of the Neuromuscular Study Group. Salam S, et al. Among authors: barohn rj. J Neurol Neurosurg Psychiatry. 2024 Jul 11:jnnp-2024-333617. doi: 10.1136/jnnp-2024-333617. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38960586
Conducting a bayesian multi-armed trial with response adaptive randomization for comparative effectiveness of medications for CSPN.
Brown AR, Gajewski BJ, Mudaranthakam DP, Pasnoor M, Dimachkie MM, Jawdat O, Herbelin L, Mayo MS, Barohn RJ. Brown AR, et al. Among authors: barohn rj. Contemp Clin Trials Commun. 2023 Oct 14;36:101220. doi: 10.1016/j.conctc.2023.101220. eCollection 2023 Dec. Contemp Clin Trials Commun. 2023. PMID: 37965484 Free PMC article.
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Machado PM, McDermott MP, Blaettler T, Sundgreen C, Amato AA, Ciafaloni E, Freimer M, Gibson SB, Jones SM, Levine TD, Lloyd TE, Mozaffar T, Shaibani AI, Wicklund M, Rosholm A, Carstensen TD, Bonefeld K, Jørgensen AN, Phonekeo K, Heim AJ, Herbelin L, Barohn RJ, Hanna MG, Dimachkie MM; Arimoclomol in IBM Investigator Team of the Neuromuscular Study Group. Machado PM, et al. Among authors: barohn rj. Lancet Neurol. 2023 Oct;22(10):900-911. doi: 10.1016/S1474-4422(23)00275-2. Lancet Neurol. 2023. PMID: 37739573 Free article. Clinical Trial.
382 results